Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope it happens Augusta!!! tuna
Way to go with TGC Augusta!!! Bigtime congrats!! tuna
Yeah augusta...TGC looking very nice! Thanks for the chart and heads up! tuna
Yeah augusta...TGC is certainly one that can move big...and I have played it many times in the past....tuna
Awesome pick in DUNR augusta!!! Wow!!! tuna
TGC nice augusta...my SNBP at .285 is doing well but this little Chinese profitable biotech is all I have that is doing good...haha!! All the best!! tuna
LOL!!! Glad to see my Chinese SNBP .285 doing well but nothing new added million...thanks!! I'm still not certain if I'll try to get back into trading or not...maybe I can come to a decision on this in the next few months hopefully. Wishing you and everyone a wonderful December and will try to drop by before year end to say "Hi" if nothing else...
Still no idea million....but wishing you and everyone the best with it...hope everyone had a nice Thanksgiving!! tuna
Hi all...I'm giving a 20% discount beginning today on all items on http://artofeverycolor.com/ through December 31st!!! The discount is on the price of the item only as shipping/packaging will still be the actual cost to ship added to the reduced cost of the item. If anyone has an interest in determining the shipping and packaging charge on a particular item please send me you zipcode so that I can compute it. Hoping to unclutter the condo and sell several items which may be given as Christmas gifts or for something for yourself! The rest of the public will get the discount beginning Nov. 10th but wanted old friends from here to have an earlier chance. Please email me at darryllar@q.com if any questions.
Still in my same 3 penny stocks...and will continue to hold 'em. purposely put this in while trading is off so as not to disrupt things...all the best everyone!!! tuna
Hope it didn't get too bad there wick...haven't been around lately and likely won't be for some time...best of luck!! tuna
Thankyou lee!! It's finally cooling down in sunny Arizona and I'm glad to see it after a cool week in Illinois/Indiana for a family reunion last week. I was lucky to miss the 106-112 temps in Arizona and had mostly 80's in the midwest. Upon returning it's high 90's now here...sweet!! Take care lee and all the best!! tuna
Nice info on SHZ wick...thanks! All the best to you and everyone else on the board! tuna
Just back from Indiana/Illinois...will take a look at SHZ and best of luck to you and everyone else wick! tuna
Still like SNBP .27 -.01 with good news yesterday...also for anyone interested in art/collectibles, I added about 10 new items yesterday to my website artofeverycolor.com
Here is the news on SNBP which has had several nice PR's:
:14 am EDT
NANTONG CITY, China, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or the "Company"), an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. ("Lianhuan") to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases. Sinobiopharma is the first Chinese pharmaceutical company that received the approval from the Chinese State FDA for clinical trial of Eplerenone in China. If successfully commercialized, the Company anticipates that Eplerenone will enjoy multi-year market exclusivity based on its first-to-market status.
Under the terms of the agreement, upon successful launch of the product, Sinobiopharma will receive 60% of Eplerenone's profits while Lianhuan is entitled to the balance. Sinobiopharma has received authorization from the China State Food and Drug Administration (SFDA) to commence clinical trials. Lianhuan has agreed to execute and fund the cost of clinical development, regulatory applications and manufacturing of Eplerenone. The companies intend to jointly market Eplerenone based on their different geographical strengths in China.
"We are pleased to collaborate with a high quality, strong partner like Jiangsu Lianhuan," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We are highly optimistic about Eplerenone and believe that it could be an important growth driver, thanks to our first mover advantage with this compound and high technical barrier which would limit potential competition."
About Eplerenone
Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is specifically used for reducing cardiovascular risk in patients following myocardial infarction.
About Jiangsu Lianhuan Pharmaceuticals Co., Ltd.:
Lianhuan is a China-listed pharmaceutical company located in the Yangzhou, Jiangsu province of China. Lianhuan was established in 1958 and employs 1100 people. The company has GMP certified production lines, a strong research and development capability and occupies 190,000 square meters. For more information, visit: http://www.lhpharma.com/english/default.htm
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., Sinobiopharma's wholly-owned subsidiary in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.James Mu, CFO86-25-5806-1579xjmu@sinobiopharma.com
Best of luck all....tuna
Also...I put up about 10 new items on artofeverycolor.com for any with interest in art/home decor area...tuna
Yeah and even more good news on SNBP .27 yesterday: :14 am EDT
NANTONG CITY, China, Aug. 10, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or the "Company"), an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. ("Lianhuan") to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases. Sinobiopharma is the first Chinese pharmaceutical company that received the approval from the Chinese State FDA for clinical trial of Eplerenone in China. If successfully commercialized, the Company anticipates that Eplerenone will enjoy multi-year market exclusivity based on its first-to-market status.
Under the terms of the agreement, upon successful launch of the product, Sinobiopharma will receive 60% of Eplerenone's profits while Lianhuan is entitled to the balance. Sinobiopharma has received authorization from the China State Food and Drug Administration (SFDA) to commence clinical trials. Lianhuan has agreed to execute and fund the cost of clinical development, regulatory applications and manufacturing of Eplerenone. The companies intend to jointly market Eplerenone based on their different geographical strengths in China.
"We are pleased to collaborate with a high quality, strong partner like Jiangsu Lianhuan," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We are highly optimistic about Eplerenone and believe that it could be an important growth driver, thanks to our first mover advantage with this compound and high technical barrier which would limit potential competition."
About Eplerenone
Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is specifically used for reducing cardiovascular risk in patients following myocardial infarction.
About Jiangsu Lianhuan Pharmaceuticals Co., Ltd.:
Lianhuan is a China-listed pharmaceutical company located in the Yangzhou, Jiangsu province of China. Lianhuan was established in 1958 and employs 1100 people. The company has GMP certified production lines, a strong research and development capability and occupies 190,000 square meters. For more information, visit: http://www.lhpharma.com/english/default.htm
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., Sinobiopharma's wholly-owned subsidiary in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.James Mu, CFO86-25-5806-1579xjmu@sinobiopharma.com
It's day will come imho...even if I wait for a year or more I'm very willing! All the best! tuna
that is a heck of a move wick...congrats...hope you got a lot of it! Leaving later this month for a week...and too busy to trade right now but happy so can't complain much....haha! Enjoy the big market run while it lasts....Darryl
Thanks Lee!! I'm enjoying the reduced stress with my art website and letting the trading go. Not as exciting for sure, but at my age I guess I can do with a little less excitement...haha! tuna
Hi all...haven't been around trading though holding SNBP .28 my fast growing and profitable Chinese biotech. Have added quite a few nice items to the art website: artofeverycolor.com for anyone interested in a wide array of art.
SNBP has been holding above it's 50/200 dma's recently and the recent news has been quite favorable...here is the latest pr:
Sinobiopharma Announces Agreement to Manufacture and Co-Promote Two Products
Tuesday July 20, 2010, 8:00 am EDT
NANTONG CITY, China, July 20, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or, the "Company") is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd ("Xianfeng") to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
Sinobiopharma owns the drug certificates, drug registration approval documents and production technologies of both products. Under the terms of the agreement, Xianfeng will pay Sinobiopharma for access to the technologies and Sinobiopharma will pay Xianfeng for manufacturing the drugs. Due to the large manufacturing capability of Xianfeng, the production cost will be significantly reduced. The companies will jointly market the products. Financial details of the transactions have not been disclosed.
"Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma."
About Clindamycin and Gueran
Clindamycin is an antibiotic used to treat anaerobic bacterial infections. It can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne and can be useful against some methicillin-resistant bacteria. L-alanyl-L-glutamine is a parenteral nutrition prescribed for patients following surgery.
About Anhui Xianfeng Pharmaceuticals Co., Ltd:
Xianfeng is a privately owned pharmaceutical company located in Hefei, Anhui province in China. Xianfeng was established in 2002. The company has GMP certified production lines and a large manufacturing capability.
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.James Mu, CFO86-25-5806-1579xjmu@sinobiopharma.com
Wishing everyone the best...probably won't get back into trading too soon...strange market and I didn't do well last trip back...take care!! tuna
Looks like it's pulled back just under a buck here but will monitor MTLK wick...thanks! tuna
Will do million and I'm still holding Chinese SNBP .28 hit .29 this morning...here was the last news on it:
Sinobiopharma Announces Agreement to Manufacture and Co-Promote Two Products
Share
retweet
EmailPrint..Companies:SINOBIOPHARMA, INC.Related Quotes
Symbol Price Change
SNBP.OB 0.28 0.00
{"s" : "snbp.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Sinobiopharma, Inc. On Tuesday July 20, 2010, 8:00 am EDT
NANTONG CITY, China, July 20, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or, the "Company") is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd ("Xianfeng") to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
Sinobiopharma owns the drug certificates, drug registration approval documents and production technologies of both products. Under the terms of the agreement, Xianfeng will pay Sinobiopharma for access to the technologies and Sinobiopharma will pay Xianfeng for manufacturing the drugs. Due to the large manufacturing capability of Xianfeng, the production cost will be significantly reduced. The companies will jointly market the products. Financial details of the transactions have not been disclosed.
"Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma."
About Clindamycin and Gueran
Clindamycin is an antibiotic used to treat anaerobic bacterial infections. It can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne and can be useful against some methicillin-resistant bacteria. L-alanyl-L-glutamine is a parenteral nutrition prescribed for patients following surgery.
About Anhui Xianfeng Pharmaceuticals Co., Ltd:
Xianfeng is a privately owned pharmaceutical company located in Hefei, Anhui province in China. Xianfeng was established in 2002. The company has GMP certified production lines and a large manufacturing capability.
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.James Mu, CFO86-25-5806-1579xjmu@sinobiopharma.com
Holding above the 50 and 200 dma's and looking very good imho...profitable and growing rapidly is a nice combination! All the best...tuna
Wick...SBNP .28 unch. doing very well, above 50 and 200 dma for close to 2 weeks now...here was the last pr:
Sinobiopharma Announces Agreement to Manufacture and Co-Promote Two Products
Share
retweet
EmailPrint..Companies:SINOBIOPHARMA, INC.Related Quotes
Symbol Price Change
SNBP.OB 0.28 0.00
{"s" : "snbp.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Sinobiopharma, Inc. On Tuesday July 20, 2010, 8:00 am EDT
NANTONG CITY, China, July 20, 2010 (GLOBE NEWSWIRE) -- Sinobiopharma, Inc. (OTCBB:SNBP - News) ("Sinobiopharma" or, the "Company") is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd ("Xianfeng") to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
Sinobiopharma owns the drug certificates, drug registration approval documents and production technologies of both products. Under the terms of the agreement, Xianfeng will pay Sinobiopharma for access to the technologies and Sinobiopharma will pay Xianfeng for manufacturing the drugs. Due to the large manufacturing capability of Xianfeng, the production cost will be significantly reduced. The companies will jointly market the products. Financial details of the transactions have not been disclosed.
"Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner," said Dr. Lequn Lee Huang, Chairman and Chief Executive Officer of Sinobiopharma. "We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma."
About Clindamycin and Gueran
Clindamycin is an antibiotic used to treat anaerobic bacterial infections. It can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne and can be useful against some methicillin-resistant bacteria. L-alanyl-L-glutamine is a parenteral nutrition prescribed for patients following surgery.
About Anhui Xianfeng Pharmaceuticals Co., Ltd:
Xianfeng is a privately owned pharmaceutical company located in Hefei, Anhui province in China. Xianfeng was established in 2002. The company has GMP certified production lines and a large manufacturing capability.
About Sinobiopharma, Inc.
Sinobiopharma is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Sinobiopharma has patented new methods for synthesizing active pharmaceutical ingredients (API) at a lower cost and owns drug delivery formulations that improve usability. For additional information, please visit the Company's website at: www.sinobp.com.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.
Contact:
Sinobiopharma, Inc.James Mu, CFO86-25-5806-1579xjmu@sinobiopharma.com
GL with all your holdings and keep an eye on this profitable Chinese gem too imho...tuna
Nice million...TSYS has been one I've traded several times in the past...GL!! tuna
Yeah salen....liking that SNBP has a .65 target on it's new coverage received this week...expecting this company to do very well over time! tuna
Thanks for the info...SNBP at .23 has a new 12 mos. target of .65 on the new coverage of the company also...GL! tuna
Thanks salen, and nice news on SNBP .24 today coming back on 2 recent good PR's:
•Sinobiopharma Announces Coverage by Harbinger Research
GlobeNewswire(Thu 8:00AM EDT)
•SINOBIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online(Tue, Jul 6)
•Sinobiopharma Announces Distribution Contracts for Flagship Product Totaling US$8.4 Million
GlobeNewswire(Tue, Jul 6)
I'm still in this one and will continue to hold!! All the best to you and everyone here!! tuna
Cool on GOK wick...also SNBP looking very good imho...GL!! tuna
Chinese SNBP .24 +.02 on strong news lately:
•Sinobiopharma Announces Coverage by Harbinger Research
GlobeNewswire(Thu 8:00AM EDT)
•SINOBIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online(Tue, Jul 6)
•Sinobiopharma Announces Distribution Contracts for Flagship Product Totaling US$8.4 Million
GlobeNewswire(Tue, Jul 6) Just passing by and saw the info...still in this one in a big way...all the best to everyone! tuna
Yeah wick...MILL was a real winner for sure...thanks for it!! tuna
Hope AROX continues to go million if you're still in! tuna
Hey salen....sorry I haven't checked in for some time...busy with other things and not trading for several weeks now and I see the market is acting poorly again...may stay away for awhile longer I think, but wishing you and everyone the best!! tuna
Thanks TK...will check out EGHT again...SNBP .23 is my favorite long term stock which is also profitable...Chinese biotech! GL...tuna
Yeah wick...LLEN under 9 looks very good!! tuna
Thanks!! Enjoy the holiday weekend everyone...tuna
Thanks wick...GL on your trades! tuna
Thanks Tarantula and sorry for your hits too! Wacky stock market action this week again! Enjoy the weekend in any case! tuna
Nothing new Tarantula...kind of a tough market again...GL!! tuna
Not doing any new buying Tanaka at least for right now...wishing everyone the best here...tuna
Nice Tanaka...yes it was a really nice weekend...SNBP is back to .21 today I see though....grrrrr! Oh well a buying op for others who had more patience to hold off buying in the mid .20's! All the best! tuna
Thanks for the earnings wick....GL! tuna